Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 08-13-2025 | 06-30-2025 | 10-Q | |
| 2 | 05-14-2025 | 03-31-2025 | 10-Q | |
| 3 | 03-19-2025 | 12-31-2024 | 10-K | |
| 4 | 11-13-2024 | 09-30-2024 | 10-Q | |
| 5 | 08-13-2024 | 06-30-2024 | 10-Q |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Alumis (NASDAQ:ALMS) with a Buy and maintains $14 price target.
Alumis (NASDAQ:ALMS) reported quarterly sales of $2.67 million which beat the analyst consensus estimate of $2.00 million by 33...
Wells Fargo analyst Derek Archila initiates coverage on Alumis (NASDAQ:ALMS) with a Overweight rating and announces Price Ta...
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Alumis (NASDAQ:ALMS) with a Buy and maintains $14 price target.
Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immun...
- SEC Filing
Guggenheim analyst Yatin Suneja reinstates Alumis (NASDAQ:ALMS) with a Buy and announces $18 price target.
